Organigram Holdings Inc. (TSE:OGI – Get Rating) has earned an average rating of “Moderate Buy” from the eight analysts that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is C$2.15.
Several brokerages recently issued reports on OGI. Jefferies Financial Group reduced their target price on Organigram from C$2.60 to C$2.00 in a research report on Friday, December 23rd. Stifel Nicolaus raised Organigram from a “hold” rating to a “buy” rating in a report on Friday. Finally, Alliance Global Partners reduced their price target on Organigram from C$1.50 to C$1.30 in a report on Friday.
Organigram Trading Down 0.8 %
Shares of TSE:OGI opened at C$1.32 on Tuesday. The stock’s 50-day simple moving average is C$1.25 and its two-hundred day simple moving average is C$1.31. Organigram has a 52-week low of C$0.96 and a 52-week high of C$2.32. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.62 and a current ratio of 4.01. The stock has a market capitalization of C$414.29 million and a price-to-earnings ratio of -11.19.
Organigram Company Profile
Organigram Holdings Inc, through its subsidiaries, engages in the production and sale of cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, gummies, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the SHRED, Big Bag O' Buds, Monjour, SHRED'ems, Edison Cannabis Co, Edison JOLTS, Tremblant, and Laurentian brands; and cannabis edibles products and concentrates.
- Don’t Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Is Macau a Sinking Ship for Wynn Resorts?
- Why Warner Bros Discovery Is the S&P’s Hottest Stock
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
- Pinterest is the Social Commerce Platform to Watch in 2023
Receive News & Ratings for Organigram Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Organigram and related companies with MarketBeat.com's FREE daily email newsletter.